Erratum: Protein phosphatase PP5 controls bone mass and the negative effects of rosiglitazone on bone through reciprocal regulation of PPAR (peroxisome proliferator-activated receptor ) and RUNX2 (runt-related transcription factor 2) (Journal of Biological Chemistry (2016) 291 (24475–24486) DOI: 10.1074/jbc.M116.752493)

This article has been withdrawn by the authors following concerns raised by the Journal. Specifically, the image for total ERK in Fig. 1A was incorrectly used in Ge et al. (Ge, C., Wang, Z., Zhao, G., Li, B., Liao, J., Sun, H., and Franceschi, R. T. (2016) Discoidin receptor 2 controls bone formation and marrow adipogenesis. J. Bone Miner. Res. 31, 2193–2203). Also, the Journal had concerns about the data integrity related to immunoblots in Fig. 2A. The authors believe that the responsible course of action is to withdraw the article to maintain their publication standards and those of the Journal. However, the authors stand by the overall conclusions of Fig. 2A that, in the authors’ opinion, has been verified using a different cell line in Fig. 4E of the same article and subsequently and independently verified in Fig. 4L of Wang et al. (Wang, J., Cao, Y., Qiu, B., Du, J., Wang, T., Wang, C., Deng, R., Shi, X., Gao, K., Xie, Z., and Yong, W. (2018) Ablation of protein phosphatase 5 (PP5) leads to enhanced both bone and cartilage development in mice. Cell Death Dis. 9, 214). The withdrawn manuscript is available from the authors upon request.